Full text is available at the source.
Abstract
The comparative impact of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in type 2 diabetes patients remains unclear.
- SGLT2 inhibitors and GLP-1 receptor agonists may offer metabolic and anti-inflammatory benefits.
- These benefits could potentially influence the risk of osteoarthritis in patients with type 2 diabetes.
- The study aims to evaluate and compare the effects of these two drug classes on osteoarthritis incidence.
Simplified